Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Crohns disease is a long-lasting condition causing severe inflammation in the digestive tract, mainly affecting the bowels. Symptoms include belly pain, diarrhea, tiredness, and weight loss. This study evaluates targeted therapies for adults with moderate to severe Crohns disease, aiming to understand their effectiveness and side effects. The trial is a Phase 2a randomized platform study involving about 590 participants worldwide. Participants will be randomly assigned to receive one of several treatments risankizumab, trosunilimab, lutikizumab, or ABBV-8736, administered either by injection under the skin or infusion into the vein. Some groups receive combination therapies involving different doses and delivery methods. A long-term extension allows risankizumab monotherapy for up to 72 weeks. Treatments are given at hospitals or clinics in scheduled visits. During the study, participants attend regular visits for medical assessments including blood tests, endoscopies, and questionnaires. Researchers monitor treatment effects, side effects, and disease activity using tools like endoscopic remission and clinical remission scores. Safety and adverse events are tracked up to approximately 96 weeks. Participants keep daily diaries and complete questionnaires to aid data collection.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VE303, a live biotherapeutic product, in preventing the recurrence of Clostridioides difficile infection CDI. This study focuses on participants with either recurrent CDI or primary CDI at high risk for recurrence, assessing the recurrence rate at 8 weeks after treatment. The study is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Vedanta Biosciences, Inc. Participants receive either VE303 or a matching placebo after completing 10 to 21 days of standard antibiotic treatment for their CDI episode. Those assigned to the VE303 group take 3 capsules daily for 14 days the placebo group takes 3 placebo capsules daily for the same duration. The capsules look identical to ensure blinding. This treatment period follows the completion of their initial antibiotic therapy. Throughout the study, participants are monitored for CDI recurrence up to 8 weeks after treatment. Researchers evaluate safety and measure the rate of CDI coming back during this period. Participants must have completed standard antibiotic therapy and meet clinical stability criteria before starting the study drug. The total participation time includes screening, treatment, and observation phases until the primary outcome at week 8 is assessed.